HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The role of histone deacetylases (HDACs) in the tumor immune microenvironment of gynecologic cancers is not well understood.
• HDACs are a class of enzymes involved in gene regulation and cellular processes.

Purpose of the Study:

• To investigate the expression and function of HDACs in gynecologic tumors.
• To explore the impact of HDACs on the tumor immune microenvironment and patient prognosis.
• To evaluate the therapeutic potential of HDAC inhibitors in combination with immunotherapy.

Main Methods:

• Integrated analysis of The Cancer Genome Atlas and Human Protein Atlas data for HDAC expression in breast, cervical, ovarian, and endometrial cancers.
• Gene Set Enrichment Analysis (GSEA) to assess associations with proliferation and inflammation signatures.
• Murine 4T1 breast cancer model treated with suberoylanilide hydroxamic acid (SAHA) and PD-1 antibody.
• Real-time polymerase chain reaction (PCR) to analyze gene expression changes.

Main Results:

• Elevated HDAC expression correlated with poor prognosis and aggressive cancer subtypes.
• HDACs were associated with increased tumor proliferation and decreased immune cell infiltration (NK, NKT, CD8+ T cells).
• SAHA and PD-1 antibody treatment inhibited tumor growth and enhanced CD3+/CD8+ T cell infiltration, upregulating immune-related genes and downregulating oncogenes.

Conclusions:

• HDACs exhibit tumor-promoting and immunosuppressive functions in gynecologic cancers.
• HDAC inhibitors represent a promising therapeutic strategy for gynecologic cancers, potentially by reactivating anti-tumor immunity.